Traders should monitor upcoming SCY-247 Phase 1 topline data in late 2026 and potential milestone payments from GSK on BREXAFEMME sales, which could provide additional non-dilutive funding and catalyze further value creation.
Price Chart
Executive Summary
Scynexis reported a significant year-over-year revenue increase to $20.6 million in 2025, driven by a $24.8 million one-time payment and catchup revenue from GSK, while R&D and SG&A expenses declined. The company ended the year with $56.3 million in cash, providing a runway of over two years, and advanced its SCY-247 program with Phase 1 IV dosing initiated and expanded access planned for 2026.
Key Financial Metrics
Key Facts
- Revenue surged to $20.6 million in 2025 from $3.7 million in 2024, primarily due to $24.8 million in non-refundable payments and catchup revenue from GSK.
- Net loss narrowed to $8.6 million from $21.3 million in 2024, with R&D expenses decreasing 15.6% year-over-year.
- Cash, cash equivalents, and investments totaled $56.3 million as of December 31, 2025, providing a cash runway of more than two years.
- SCY-247 IV formulation Phase 1 dosing initiated in February 2026, with topline data expected in second half of 2026; expanded access program planned for first half of 2026.
- FDA granted QIDP and Fast Track designations for SCY-247 in January 2026.
Financial Impact
Revenue increased by $16.9 million YoY; cash position improved by $24.8 million from GSK payment despite operating outflows.
Risk Factors
- Future revenue is heavily dependent on GSK's commercial success with BREXAFEMME and potential milestone payments.
- SCY-247 development remains early-stage; clinical setbacks could impact valuation and funding strategy.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3249748 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 10, 2026 22d ago | 8-K | $4.70 $4.45 | ▼ −5.32% | ▼ −4.82% | $5.12 (+8.94%) |
Jun 26, 2026 14w ago | 8-K | $3.87 $4.73 | ▲ +22.22% | ▲ +20.83% | $5.12 (+32.30%) |
May 22, 2026 19w ago | 8-K | $5.45 $5.33 | ▼ −2.17% | ▼ −3.25% | $5.12 (−6.02%) |
May 11, 2026 20w ago | Press Release | $6.24 $5.26 | ▲ +15.77% | ▲ +15.17% | $5.12 (+17.95%) |
Apr 20, 2026 23w ago | 8-K | $8.48 $7.89 | ▼ −6.98% | ▼ −8.06% | $5.12 (−39.62%) |
Mar 31, 2026 26w ago | Press Release | $7.34 $7.97 | ▲ +8.62% | ▲ +4.67% | $5.12 (−30.21%) |
Mar 4, 2026 30w ago | Press Release | $6.34 $7.12 | ▲ +12.34% | ▲ +14.58% | $5.12 (−19.24%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access